On February 2, 2026, the FDA’s revised Quality Management System Regulation (QMSR) officially became effective, replacing the long-standing Quality System (QS) Regulation framework under 21 CFR Part 820.
While the transition has often been described as a “harmonization” exercise, the practical implications extend well beyond terminology changes. The revised framework fundamentally changes how FDA evaluates medical device quality systems by aligning U.S. requirements more closely with ISO 13485:2016 and modernizing the agency’s inspection approach.
For many manufacturers, particularly those already operating internationally, the transition may initially appear administrative in nature. However, the implementation of QMSR also signals a broader regulatory shift toward lifecycle-based quality oversight, expanded inspection authority, and greater emphasis on documented system effectiveness rather than procedural formality alone.
As FDA begins conducting inspections under the new framework, manufacturers are entering a different regulatory environment — one where alignment with ISO 13485 is no longer supplemental to FDA compliance, but central to it.
The FDA finalized the QMSR rule in January 2024, with a two-year implementation period that culminated in the February 2, 2026 effective date.
The revised regulation replaces large portions of the legacy Quality System Regulation by incorporating ISO 13485:2016 by reference while preserving certain FDA-specific requirements necessary under the Federal Food, Drug, and Cosmetic Act.
The objective of the transition is not simply regulatory modernization. FDA has consistently framed the rule as part of a broader harmonization effort intended to reduce duplication between U.S. and international quality management requirements while improving consistency across global regulatory systems.
Historically, medical device manufacturers operating internationally often maintained parallel systems to satisfy both FDA Quality System Regulation requirements and ISO 13485 expectations. In practice, this created operational inefficiencies, duplicated documentation activities, and conflicting interpretations between regulators and notified bodies.
Under QMSR, FDA has effectively adopted ISO 13485:2016 as the foundation of device quality management oversight while introducing supplemental provisions to maintain alignment with existing FDA statutory requirements.
Importantly, the scope of FDA oversight has not narrowed. The revised regulation continues to apply broadly across the medical device lifecycle, including activities related to design, manufacturing, packaging, labeling, storage, installation, and servicing.
The transition also does not eliminate FDA inspections or replace FDA authority with third-party certification programs. FDA has explicitly clarified that ISO 13485 certification does not exempt manufacturers from inspection and that FDA inspections will continue to assess compliance with FDA regulatory requirements rather than simple conformance to a voluntary standard.
It is also important to recognize that FDA inspections themselves do not result in ISO 13485 certification. Organizations seeking certification must continue to work with an accredited certification body, as FDA inspection outcomes and ISO certification remain separate regulatory processes.
Manufacturers participating in the Medical Device Single Audit Program (MDSAP) will continue to be exempt from routine FDA surveillance inspections. However, FDA retains the authority to conduct premarket approval inspections, as well as for-cause inspections when warranted. Participation in MDSAP should therefore be viewed as reducing routine inspection burden rather than eliminating FDA oversight altogether.
Although many core quality system principles remain familiar, several important operational and inspection-related changes took effect in February 2026.
FDA formally aligned Part 820 with ISO 13485:2016
The most significant structural change is the incorporation of ISO 13485:2016 into the FDA regulatory framework.
FDA determined that ISO 13485 requirements are “substantially similar” to the former QS Regulation and provide a comparable level of assurance regarding device safety, effectiveness, and quality system control.
This alignment introduces a more internationally integrated quality system model centered on:
For organizations already certified to ISO 13485, the transition may reduce certain areas of redundancy. However, FDA-specific obligations remain fully enforceable, particularly in areas tied directly to statutory requirements such as complaint handling, MDR obligations, and records accessibility.
Although QMSR incorporates ISO 13485:2016, manufacturers must continue to comply with several FDA-specific regulatory requirements that remain outside the scope of the international standard.
These requirements continue to apply independently of ISO 13485 certification and should remain integrated within an organization’s quality management and regulatory compliance program. Key FDA-specific requirements include:
While QMSR reduces many of the historical differences between FDA and international quality management requirements, it does not replace these statutory obligations. Manufacturers should ensure that their quality management systems continue to address both ISO 13485 requirements and these FDA-specific regulatory responsibilities.
One of the most operationally significant changes accompanying QMSR is the retirement of the Quality System Inspection Technique (QSIT).
As of February 2, 2026, FDA transitioned device inspections to a revised inspection model under Compliance Program 7382.850.
This matters because the historical QSIT structure shaped how many manufacturers prepared for FDA inspections over the past two decades. Under the updated framework, inspections are expected to align more closely with ISO 13485 concepts and broader system-level quality interactions.
The shift reflects FDA’s movement away from highly segmented inspection approaches toward more integrated evaluation of quality system effectiveness across the product lifecycle.
One of the most discussed changes under QMSR involves inspectional access to records that were previously exempt under 21 CFR 820.180(c).
Under the former QS Regulation, FDA investigators generally did not review certain documents during inspections, including:
Under QMSR, those exemptions no longer apply. FDA has clarified that investigators may now review these records during inspections conducted on or after February 2, 2026.
This represents a meaningful shift in inspection expectations.
Historically, many organizations treated management review and internal audit activities as partially insulated from direct FDA scrutiny. Under QMSR, those records become part of the broader evidentiary framework FDA may use to assess whether a quality system is functioning effectively in practice.
As a result, organizations may need to reassess not only the completeness of these activities, but also how findings, escalation decisions, supplier oversight, and executive management engagement are documented.
The revised framework also reflects a broader regulatory movement toward lifecycle quality management rather than isolated procedural compliance.
ISO 13485 emphasizes ongoing risk management, supplier oversight, postmarket feedback integration, and continuous quality system maintenance across the entire device lifecycle. FDA’s adoption of this structure reinforces expectations that manufacturers maintain active control systems rather than static procedural documentation.
This aligns with broader global regulatory trends already visible under frameworks such as:
In practice, regulators are increasingly focused on whether organizations can demonstrate sustained system effectiveness, traceability, and decision-making accountability over time.
For many device manufacturers, the largest challenge under QMSR is unlikely to be rewriting procedures. The more significant challenge will be demonstrating that quality systems operate cohesively, consistently, and transparently under increased regulatory scrutiny.
Organizations that previously approached FDA compliance and ISO certification as parallel activities may now need to reassess how their systems integrate across global operations.
Several areas are likely to receive heightened attention during inspections:
Because FDA may now review management review documentation directly, organizations should expect greater focus on how executive leadership evaluates quality system performance, escalates risks, allocates resources, and responds to recurring issues.
Management review activities that appear procedural rather than substantive may create additional inspection risk.
Internal audits are no longer effectively shielded from FDA review. This changes the strategic importance of audit quality, audit follow-up, and documented corrective actions.
Organizations should evaluate whether internal audit programs genuinely assess system effectiveness or simply verify procedural existence.
The harmonized framework places continued emphasis on supplier qualification, outsourced process control, and supply chain visibility.
As medical device supply chains become increasingly globalized and software-dependent, regulators are placing greater attention on how manufacturers maintain control over externally sourced components, services, and critical processes.
QMSR reinforces the expectation that records demonstrate not only procedural compliance, but also evidence-based quality decision-making.
Inspection readiness increasingly depends on whether organizations can clearly demonstrate:
This represents a more mature regulatory expectation than simply maintaining completed forms or approved procedures.
Preparation for QMSR inspections should extend beyond document updates.
Manufacturers should consider conducting a broader evaluation of how their quality systems function operationally under the revised framework, including:
Organizations may also benefit from performing comparative gap assessments between historical QS Regulation practices and current QMSR expectations to identify areas where operational execution may not fully support the revised inspection environment.
Importantly, FDA has indicated that investigators may review records created prior to February 2, 2026 as part of determining ongoing compliance under QMSR. Manufacturers should therefore ensure historical documentation remains defensible within the context of the revised framework.
The FDA’s implementation of the Quality Management System Regulation marks one of the most significant changes to medical device quality oversight in decades.
While the transition is often described as harmonization with ISO 13485, the practical impact is broader. QMSR changes how FDA evaluates quality systems, expands inspectional visibility into organizational oversight activities, and reinforces lifecycle-based expectations that increasingly align with global regulatory trends.
For manufacturers, the transition is not simply about updating terminology or revising procedures. It is about demonstrating that quality systems function as integrated, risk-aware operational frameworks capable of supporting sustained compliance, traceability, and product quality across the device lifecycle.
As inspections under the revised framework continue, organizations that proactively evaluate system maturity, documentation defensibility, and management accountability will be better positioned to navigate the evolving regulatory landscape.
At dicentra, we support medical device manufacturers through the evolving intersection of regulatory affairs, quality systems, and operational compliance.
Our team assists organizations with:
As FDA transitions fully into the QMSR inspection framework, manufacturers are facing increased expectations around system effectiveness, traceability, and lifecycle oversight. dicentra helps organizations translate those expectations into practical, inspection-ready quality systems aligned with both U.S. and international regulatory requirements.
Contact us today for support meeting QSMR and ISO 13485 requirements for your medical devices.